Posted On: 10/02/2014 11:27:48 AM
Post# of 30066
Gerald has repeatedly mentioned the following:
1. Spinning off of Diagnostics Division
2. Financial engineering to add shareholder value
3. R/S may not be necessary for uplist
I am not surprised if the Lympro data development is phased in sync with deal discussion dynamics behind the scenes. While the recent months of seemingly abrupt changes in timeline of Lympro data release may have dismayed public shareholders, it is well worth the wait if Gerald announces, say, a $2B buyout of Diagnostic Division by a BP that will bring AMBS stock price from $0.09 to $2+ instantly, fulfilling all that Gerald has conveyed regularly.
With Gerald also keeping tight-lipped on Phenoguard development as well as not passing any comments during twitter's Q&A on whether AMBS receives a buyout offer, there may be more permutations of deal structures being negotiated with interested parties at the moment.
I believe the big pay day may come anytime if Gerald means what he has repeatedly mentioned above. Be patient.
1. Spinning off of Diagnostics Division
2. Financial engineering to add shareholder value
3. R/S may not be necessary for uplist
I am not surprised if the Lympro data development is phased in sync with deal discussion dynamics behind the scenes. While the recent months of seemingly abrupt changes in timeline of Lympro data release may have dismayed public shareholders, it is well worth the wait if Gerald announces, say, a $2B buyout of Diagnostic Division by a BP that will bring AMBS stock price from $0.09 to $2+ instantly, fulfilling all that Gerald has conveyed regularly.
With Gerald also keeping tight-lipped on Phenoguard development as well as not passing any comments during twitter's Q&A on whether AMBS receives a buyout offer, there may be more permutations of deal structures being negotiated with interested parties at the moment.
I believe the big pay day may come anytime if Gerald means what he has repeatedly mentioned above. Be patient.
(0)
(0)
